C3 Awards Research Grant to Dr. Jaakko Sarparanta to Investigate Relationship Between Calpain 3 Activity and the Protein Titin

C3 SUPPORTS RESEARCH GROUP FOR NEUROMUSCULAR DISEASES Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Jaakko Sarparanta, researcher at the Research Group for Neuromuscular Diseases led by Dr. Bjarne Udd at Folkhälsan Research Center and Department of Medical Genetics, University of Helsinki, Finland. The project, titled “CAPN3-mediated proteolytic processing of…

Read More

New report confirms calpainopathy is most common type of LGMD

A paper recently published by Madhuri Hegde, Emory University, and colleagues analyzed the outcomes of genetically sequencing a large group of patients with limb girdle weakness in the United States. This study is unique in that it included a very large cohort of patients – 4656 – who were enrolled in the Muscular Dystrophy Association…

Read More

C3 Scientific Conference 2018

On September 12 – 13, 2018, Coalition to Cure Calpain 3 hosted the “C3 Scientific Conference” in Arlington, Virginia. In attendance were prominent neuromuscular clinicians, world renowned research scientists from academia and industry, and  representatives from various funding agencies. This included C3’s Scientific Advisory Board and C3 grant recipients. The goal of the conference was…

Read More

C3 Presents at World Muscle Society Congress

Coalition to Cure Calpain 3 (C3) attended the 23rd International Annual Congress of the World Muscle Society, October 2-6 2018 in Mendoza, Argentina. Dr. Jennifer Levy, C3 Scientific Director, represented C3 and presented a poster detailing our mission, registry, and research grants program. Attendees include neuromuscular clinicians, academics, research scientists, and industry leaders from around the…

Read More

Coalition to Cure Calpain 3 Provides Gene Therapy Initiative Updates

Two new research projects funded to explore potential treatments for calpainopathy/LGMD2A $500,000+ committed to gene therapy research since initiative launched in 2017 Coalition to Cure Calpain 3 (C3), a non-profit patient advocacy organization focused on identifying and advancing potential treatments for limb-girdle muscular dystrophy type 2A/calpainopathy (LGMD2A), today announced updates to its Gene Therapy Initiative….

Read More

C3 Awards Gene Therapy Initiative Grant to Dr. Zarife Sahenk

FOURTH GENE THERAPY INITIATIVE GRANT SUPPORTS PROMISING RESEARCH AT NATIONWIDE CHILDREN’S HOSPITAL Coalition to Cure Calpain 3 (C3) is excited to announce that a new research grant has been awarded to Dr. Zarife Sahenk, Professor of Pediatrics and Neurology at Nationwide Children’s Hospital, to assess the safety and efficacy of adeno-associated viral (AAV)-mediated gene therapy in a mouse model…

Read More

Coalition to Cure Calpain 3 Awards Grant to Dr. Kathryn Wagner

Coalition to Cure Calpain 3 (C3) is pleased to announce that we are funding a new research grant to Dr. Kathryn Wagner.  Dr. Wagner, Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine, will investigate “Targeting Mss51 as…

Read More

DID YOU KNOW … there are two ways that calpainopathy can be inherited?

In over 90% of calpainopathy cases, it is inherited in an autosomal recessive manner. This means that it can be passed on through families, and that siblings can have the disease. This form of calpainopathy is called Limb Girdle Muscular Dystrophy type 2A (LGMD2A). In this recessive form, for LGMD2A to develop, two copies of the…

Read More

Do you have genetic confirmation of your LGMD diagnosis?

Limb Girdle Muscular Dystrophies (LGMDs) were characterized in the clinic before anyone knew what caused the diseases. Consequently, a bunch of different diseases that all looked the same to physicians were lumped together into one category that they called “LGMD.” As science advanced, it was discovered that many different genetic mutations underlie these conditions. Currently,…

Read More